GWP.L Share News (GWP)

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead

UK Earnings, Trading Statements Calendar - Week Ahead

UPDATE 1-Biotechs see heavy action after drug study results

(Updates to market open) By Ryan Vlastelica NEW YORK, Jan 8 (Reuters) - Biotechs were among the most active shares on Thursday, recording some of their biggest one-day moves on the back of strong results from drug studies. While other issues in the sector posted big drops tied t

BUZZ-U.S. STOCKS ON THE MOVE-AOL, Ford, Knightbridge, Mistras, Valeant

(Adds Yahoo, Sunedison, Impax, Knightsbridge, Global Payment, Agrium, Amicus, Broadwind; Updates American Eagle, Valeant) (For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Mornin

UPDATE 2-GW Pharma's cannabis drug fails in cancer pain study

* Sativex misses goal in first Phase III cancer pain study * Two further studies to report results later this year * GW shares bounce back after falling as much as 21 pct (Updates with share price recovery) By Ben Hirschler LONDON, Jan 8 (Reuters) - An experimental canna

BUZZ-U.S. STOCKS ON THE MOVE-Aeropostale, Ford, Bind Therapeutics

(Adds Ford, Alcatel-Lucent, Acura, Aveo, Banco Santander, CytRx) (For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)Read more

BUZZ-GW Pharmaceuticals Plc: Cannabis drug fails cancer pain trial

** London-listed stock down 3.9 pct at 378.50 pence; U.S.-listed stock down 2.8 pct at $69.10 premarket ** Company's experimental cannabis drug failed to alleviate pain in cancer patients in a late-stage clinical study ** Sativex, being developed with Japan's Otsuka Corp , is approved

Biotechs soar in premarket; many have strong drug data

By Ryan Vlastelica NEW YORK, Jan 8 (Reuters) - Biotech stocks were among the biggest movers during premarket trading on Thursday, with companies making up more than half of the top 25 most active Nasdaq shares and many reporting massive gains on the back of drug study data. The advanc

BUZZ-U.S. STOCKS ON THE MOVE-Aeropostale, Apollo, GW Pharma

(Adds Pioneer Energy, GW, American Eagle, Aeropostale; Updates Constellation Brands, AbbVie) (For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http:

GW Pharma's cannabis drug fails in cancer pain study

LONDON, Jan 8 (Reuters) - An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study, sending shares in its British maker GW Pharmaceuticals 18 percent lower on Thursday. GW, which is developing the drug Sativex for pain in collaboration with Japa